3 completed, 2 terminated, 1 recruiting. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 2, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow difelikefalin: new trials by email Literature Review of difelikefalin trials Research Report on difelikefalin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus Difelikefalin - Pruritus, Chronic Kidney Diseases | Phase 2 | Recruiting | Vifor Fresenius Medical Care Renal Pharma | 18 | 2026-08-04 | 2026-10-23 |
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets - Pruritus, Notalgia Paresthetica | Phase 2 / Phase 3 | Terminated | Cara Therapeutics, Inc. | 214 | 2023-08-01 | 2024-06-21 |
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT) difelikefalin 2.0 mg, Placebo - Pruritus, Notalgia Paresthetica | Phase 2 | Completed | Cara Therapeutics, Inc. | 126 | 2021-01-11 | 2023-05-22 |
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg - Pruritus, Atopic Dermatitis | Phase 2 | Completed | Cara Therapeutics, Inc. | 401 | 2019-06-29 | 2022-04-04 |
| Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus CR845 1.0 mg, Placebo - Cholestatic Pruritus | Phase 2 | Terminated | Cara Therapeutics, Inc. | 14 | 2019-06-25 | 2023-07-03 |
| A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet - Chronic Kidney Diseases, Pruritus | Phase 2 | Completed | Cara Therapeutics, Inc. | 269 | 2018-07-05 | 2024-01-24 |
Pruritus (6) · Renal Insufficiency, Chronic (2) · Dermatitis, Atopic (1) · Eczema (1) · Kidney Failure, Chronic (1) · Liver Cirrhosis, Biliary (1)
Cara Therapeutics, Inc. (5) · Vifor Fresenius Medical Care Renal Pharma (1)
United States (5) · Canada (3) · Spain (2) · China (1) · Germany (1) · Greece (1) · Israel (1) · Poland (1) · Saudi Arabia (1) · United Arab Emirates (1) · United Kingdom (1)
Kristine Nograles (1) · Nilam Shah (1)
2023 (1)